Dendrite Campaign Manager 6.0 Delivers Integrated, Multi-Channel Marketing Capabilities to Pharmaceutical Marketers; Platform E

Dendrite International, Inc. (NASDAQ: DRTE), a leading
provider of pharmaceutical industry solutions, today announced the
launch of a new version of its web based marketing solution, Dendrite
Campaign Manager(TM) 6.0 that enables pharmaceutical companies to
deliver highly targeted, multi-channel marketing campaigns to
prescribers and their patients.
   These latest advances are possible as a result of Dendrite's
recent acquisition of Optas; an important proof point of its strategy
to expand its marketing solutions offerings, to equip customers with
powerful integrated marketing and sales campaign capabilities rooted
in the deepest understanding of patient and physician preferences.
   Campaign Manager 6.0's built-in functionality enables
pharmaceutical marketers to segment and target their customers,
generate lists for execution channels, create and deploy emails and
surveys, and track campaign effectiveness. The tool's web-based
architecture enables marketers to capture opt-in registration
information, track multi-segmented campaigns and easily view all
campaign activity online.
   New built-in enhancements to Dendrite Campaign Manager 6.0 include
automated privacy compliance features that shield the pharmaceutical
marketer from inadvertently discovering or improperly using personally
identifiable information during the design and deployment of their
marketing initiatives, and to enable strict adherence to US-based
federal and state regulations, including HIPAA, CAN SPAM and the even
more rigorous European regulations.
   "When we added Optas to our portfolio of solutions, we gave our
customers a way to maximize the effectiveness of their marketing
campaigns," said Rick Rose, vice president and general manager,
Dendrite Marketing Solutions. "The release of version 6.0 expands our
leadership position in this area and provides a tremendous asset to
our clients as they look to launch and promote brands on a global
basis -- thanks not only to the automation of complex events that
allow for greater efficiencies in program management, but also, and
more importantly, to the powerful insights obtained through the
actionable data derived from this platform."

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.